Effect of PEG-rhG-CSF on preventing bone marrow suppression in patients with non-small cell lung cancer after receiving TP chemotherapy / 中国基层医药

ABSTRACT

Objective:To explore the efficacy and safety of PEGylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) on preventing bone marrow suppression in patients with non-small cell lung cancer after receiving TP chemotherapy.Methods:The clinical data of 66 cases who aged ≥ 18 years old and pathologically confirmed as non-small cell lung cancer, received postoperative TP chemotherapy in Qingyuan People's Hospital from April 2018 to March 2020 were retrospectively analyzed.According to the difference between receiving PEG-rhG-CSF and rhG-CSF after a single cycle of chemotherapy, they were divided into observation group( n=35) and control group( n=31). In the observation group, PEG-rhG-CSF was injected subcutaneously 48 h after the end of chemotherapy, 6 mg each time.In the control group, rhG-CSF was injected subcutaneously 48 h after the end of chemotherapy, 5 μg·kg -1·d -1, until the peripheral blood leukocytes were higher than 10×10 9/L.The effect of preventing bone marrow suppression was compared between the two groups. Results:After the preventive treatment, there were no statistically significant differences in the counts of white blood cells and neutrophils between the two groups on the first day, the third day and the fifth day of treatment(all P>0.05). However, there were statistically significant differences on the tenth day( t=2.417, 2.296, all P<0.05). The incidence of neutropenia in the observation group was 40.00%(14/35), which was significantly lower than that in the control group[64.52%(20/31)], the difference was statistically significant(χ 2=3.956, P=0.047). The incidence of grade 3, 4 neutropenia in the observation group was 2.86%(1/35), which was lower than that in the control group[19.35%(6/31)], the difference was statistically significant(χ 2=4.719, P=0.030). There were no statistically significant differences in the incidence of bone pain, fatigue and injection site pain between the two groups(all P>0.05). Conclusion:PEG-rhG-CSF is superior to rhG-CSF multiple-dose regimen in preventing bone marrow suppression in patients with non-small cell lung cancer after receiving TP chemotherapy, which can reduce the incidence of neutropenia and deficiency, and provide a new option for the preventive use of PEG-rhG-CSF after adjuvant chemotherapy in patients with non-small cell lung cancer.